Prevalence of Inducible Clindamycin Resistance and Methicillin Resistance among Staphylococcus Species from Various Clinical Samples in a Tertiary Care Hospital of Eastern India

Retina Paul¹, Lipika Pal², Risha Saha², Amrita Shaw³

¹Assistant Professor, Department of Microbiology, College of Medicine and JNM Hospital, WBUHS, Kalyani, Nadia, West Bengal.
²M.Sc. Student, Department of Microbiology, University of Kalyani, West Bengal.
³B.Sc. Student, Department of Biotechnology, Amity University, Kolkata, West Bengal.

Received: August 2019
Accepted: August 2019

ABSTRACT

Background: Staphylococcus species is an important cause of nosocomial and community-acquired infections worldwide. Clindamycin is an alternative agent used to treat erythromycin-resistant Staphylococcal infections. Clinical failure also reported due to various mechanisms of resistance to MLSB antibiotics. Accurate identification of clindamycin resistance is important to prevent therapeutic failure. Unfortunately, inducible clindamycin resistance is not detected by standard susceptibility tests. Aims: The aim of the present study was to detect the prevalence of inducible clindamycin and methicillin resistance among clinical isolates of Staphylococcal species via antibiotic sensitivity testing form various clinical samples. Methods: Total 153 Staphylococcal isolates were tested for antimicrobial susceptibility testing as per guidelines. For detection of MRSA cefoxitin disc and for inducible clindamycin resistance, D test was performed. Results: Out of 153 samples, 119 were Staphylococcus aureus and 34 were Coagulase negative Staphylococcus (CoNS). Out of which 62.18% were MRSA and 37.81% were MSSA. Inducible MLSB phenotype was detected in 31.09%, MS phenotype and constitutive MLSB phenotype in 42.85% and 10.08%. Conclusion: So it can be concluded from our study that D-test should be routinely performed in microbiology laboratory for every Staphylococcal isolates otherwise clindamycin resistance may be misinterpreted as clindamycin sensitive resulting in therapeutic failure.

Keywords: Clindamycin resistance, D test, MRSA, Staphylococcus aureus.

INTRODUCTION

Staphylococcus species are most common pathogen responsible for various nosocomial and community-acquired infections.[¹] 30% of normal healthy population are asymptomatically colonized Staphylococcus aureus.[²] They can produce a wide spectrum of disease starting from superficial skin infection, invasive disease to toxin-mediated life-threatening conditions.[³] Foreign materials such as indwelling catheters, implanted joints and sutures are very much susceptible to Staphylococcus epidermidis which are commonly colonized over them and act as their point of entry of the infection. Staphylococcus epidermidis are resistant to various antibiotics due to formation of biofilms. They are also served as reservoir for antibiotic-resistant genes which can be transferred to other bacteria.[⁴] Other than Staphylococcus aureus, species of Staphylococcus group are collectively referred as Coagulase negative Staphylococcus (CoNS). A special strain of Staphylococcus emerge as antibiotic-resistant refer as Methicillin resistant Staphylococcus aureus (MRSA). This strain expressed a modified penicillin binding protein (PBP-2a) encoded by mecA gene and is present in 4 forms of Staphylococcus cassette causes resistance to all ß-lactam antimicrobial agents. As Methicillin is an unstable drug, Cefoxitin is used for sensitivity testing. Cefoxitin resistance correlates with the presence of mecA gene present in all MRSA strain.[⁵]

Methicillin resistance Staphylococcus aureus (MRSA) is an increasing problem day by day.[⁶] Clindamycin is an excellent pharmacokinetics agents and useful as alternative treatment option for patients who are allergic to Penicillin for treatment of localised as well as systemic infections caused by
drug resistant Staphylococcus aureus.[7] Due to indiscriminate use of Macrolides, Lincosamide and group B Streptogramins which have a common binding site cross resistance resulting in therapeutic failure of Clindamycin. It is also an alternative choice for MRSA due to its excellent pharmacokinetics properties.[8] Clindamycin resistance in Staphylococcus species may be constitutive or inducible. Most common mechanism is target site modification by erm genes. It may express by either constitutively or inducible. In routine laboratory practise it is difficult to detect inducible clindamycin resistance if the disc is not placed adjacent to each other with maintenance of proper distance. Then in vitro the result will be erythromycin resistant and clindamycin sensitive but in vivo therapy of clindamycin may select erm mutants leading to clinical therapeutic failure.[9]

This study was conducted to investigate the prevalence of inducible Clindamycin resistance and Methicillin resistance in Staphylococcus species from different clinical samples via Antibiotic Sensitivity Test (AST) with various antibiotics from various clinical samples.

**MATERIALS AND METHODS**

The present prospective study was conducted at Microbiology department of a teaching hospital Nadia, West Bengal, eastern India during March to June 2019. A total 153 Staphylococcus species were isolated from various type of clinical specimen such as pus, wound swab, aspirates, blood, urine and sterile fluids were tested. All samples were inoculated into blood agar and Mac Conkey agar and overnight incubation done at 37°C. Then colony morphology was studied by gram stain and all gram positive cocci were tested for catalase (3%) test and identified as Staphylococcus species. Further slide and tube coagulase was performed to differentiate between Staphylococcus aureus and Coagulase negative Staphylococcus (CONS). All the isolates were further tested by standard biochemical techniques.[10] The antibiotic susceptibility test was performed in Mueller –Hinton agar plate and evaluation done by Clinical and laboratory standard institute guideline (CLSI).[11] The isolates were tested for cefoxitin (30µg), clindamycin (2 µg), erythromycin (15µg), linezolide (30µg), mupirocin(5µg), furazolidone (50µg). The inhibition zone of 22 mm or less around cefoxitin disc indicates MRSA.

Inducible clindamycin resistance was tested by ‘D test’ as per CLSI guideline. Test was performed in Mueller –Hinton agar plate which was inoculated with 0.5 McFarland standard bacterial suspensions. Then placement of erythromycin disc (15µg) at a distance of 15 mm (edge to edge) from clindamycin (2 µg) was done. Plate was incubated at 37°C overnight. Flattening of zone (D shaped around clindamycin in the area between two discs indicated inducible clindamycin resistance [Figure 1].[11]

![](figure1.png)

**RESULTS**

Out of total 2055 samples, 153 (7.44 %) clinical isolates of Staphylococcus species were obtained during the study period. Among these 153 samples, 12 (7.84 %) samples were from urine, 36 (23.5 %) samples were from blood and 105 (68.6 %) samples were from pus. Distribution of Staphylococcus species isolates of various clinical samples is shown in [Figure 2].

![](figure2.png)

Therefore, from total 153 Staphylococcus species, 119 (77.77 %) were Staphylococcus aureus and 34 (22.22 %) were CoNS. Out of 119 samples of Staphylococcus aureus, 74 (62.18 %) were MRSA, 45 (37.81 %) were MSSA. Among 34 isolates of CoNS 26 (76.47 %) were methicillin sensitive and 8 (23.52 %) were methicillin resistant. Out of 119 isolates, samples yielded (inducible MLSB phenotype) D-test positive, in Staphylococcus aureus were 37 (31.09 %) and D-test negative isolates (MS-phenotype) were 51 (42.85%). Constitutive MLSB phenotype were seen 12 (10.8 %). Both erythromycin and clindamycin sensitive were 19 (15.96 %). Percentage of inducible resistance was higher which is statistically significant [Table 1]. Positive D-test (inducible MLSB phenotype) was not observed in case of CoNS. Predominantly the isolates from inducible clindamycin resistance were from female patients were 74.1% as compare to male 25.8%.
The increase in resistance to multiple antibiotics among gram-positive cocci has left very little therapeutic options for clinicians. The emergence of multi-drug resistant organisms is significant cause of mortality and morbidity across the world. Early detection of MRSA and formulation of effective antibiotic policy has tremendous importance.

In our study majority of the isolates of Staphylococcus aureus were resistant to erythromycin (72.2%) and sensitive to clindamycin (88.1%) which is higher than (15.7% & 28.4%) two studies reported in literature. The result indicates non-judicious use of cloxacillin in health care set up.

In our study, inducible clindamycin resistance seen in 31.09 % isolates which is resembles with the results of two studies (37.5% and 33.3%) and lower rate also found in two studies (10.5% and 13.1%) reported by others. Inducible clindamycin resistance among MRSA and MSSA are 19.32 % and 11.76 %. Few studies showed higher inducible resistance in MRSA and MSSA. These result indicates that inducible clindamycin resistant phenotype may vary in different hospital set up.

Accurate susceptibility data are important for appropriate therapy decisions. The pattern of macrolide resistance in Staphylococcus aureus varies in different regions. Depending upon this the prescription rate will not be uniform in different regions. There is no substantial data regarding clindamycin prescription from India. It is kept as a reserve drug and is usually advocated in severe in-patient MRSA infections depending upon the antimicrobial susceptibility results. Further, the proper use of clindamycin in MRSA, can reduce the use of vancomycin (glycopeptide).

Accurate result can be achieved by antimicrobial susceptibility testing including the application of D-test. Thus D-test guides the clinician for the use of clindamycin which is not a suitable drug for D-test positive isolates.

**Table 1: Distribution of isolates**

<table>
<thead>
<tr>
<th>Susceptibility Pattern (Phenotype)</th>
<th>MRSA (%)</th>
<th>MSSA (%)</th>
<th>Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERY-S, CL-S</td>
<td>10 (8.40)</td>
<td>9 (7.56)</td>
<td>19 (15.96)</td>
</tr>
<tr>
<td>ERY-R, CL-R (Constitutive MLSB phenotype)</td>
<td>12 (10.8)</td>
<td>0</td>
<td>12 (10.8)</td>
</tr>
<tr>
<td>ERY-R, CL-S (D Test positive, iMLSB phenotype)</td>
<td>23 (19.32)</td>
<td>14 (11.76)</td>
<td>37 (31.09)</td>
</tr>
<tr>
<td>ERY-R, CL-S (D Test negative, MS phenotype)</td>
<td>29 (23.7)</td>
<td>22 (18.48)</td>
<td>51 (42.85)</td>
</tr>
<tr>
<td>Total</td>
<td>74 (62.18)</td>
<td>45 (38.6)</td>
<td>119 (100)</td>
</tr>
</tbody>
</table>

**DISCUSSION**

The worldwide remarkable challenge for public health is the emergence of MRSA. Based on Centres for Disease Control (CDC) reports, 1% of all Staphylococcal infections and 50 % of healthcare-associated Staphylococcal infections are caused by MRSA. It is now the common hospital acquired pathogen in many countries. Infection due to MRSA is significant cause of mortality and morbidity across world. Early detection of MRSA and formulation of effective antibiotic policy has tremendous importance. For determining appropriate therapeutic regimens, accurate detection of antimicrobial resistance in a microbe is an essential factor. This is particularly important considering the increase of resistance and the emergence of multi-drug resistant organisms. The emergence of resistant to multiple antibiotics among gram-positive cocci has left very little therapeutic options for clinicians. The increase in frequency of Staphylococcal infections among patients, and changes in antimicrobial resistance patterns have led to renewed interest in the use of clindamycin therapy.

Clindamycin (Lincosamide) has long been an attractive option to treat skin, soft tissue and bone infection due to its efficacy against Methicillin Sensitive Staphylococcus aureus (MSSA) and Methicillin Resistance Staphylococcus aureus (MRSA) for its good bone marrow and tissue penetration and potential antitoxin effects. In fact, it accumulates in abscesses and no renal dosing adjustments are needed. However, among clinical isolates there has also been a considerable increase in resistance to clindamycin including inducible resistance. The differentiation of inducible MLSB (iMLSB phenotype) isolates from isolates with (MS phenotype) resistance is a critical issue because of the therapeutic implications of using clindamycin to treat a patient with an inducible clindamycin-resistant Staphylococcus aureus isolate.

In our study the antibiogram of gram positive Staphylococcus aureus (n=119) showed the following results:

- ERY-R, CL-S (Constitutive MLSB phenotype) - 12 (10.8%) of isolates were sensitive to vancomycin (100%) and linezolide (76.2%) and mupirocin (76.2%). Sensitivity towards erythromycin was low (31.09%).
- ERY-R, CL-S (D Test positive, iMLSB phenotype) - 23 (19.32%) isolates were sensitive to vancomycin (100%) and linezolide (100%) followed by clindamycin (88.1%) and furazolidone (76.2%) and mupirocin (62.7%).
- Table 3: Antibiotic susceptibility pattern in Staphylococcus aureus (n=119)

The above table showed the antibiogram of gram positive Staphylococcus aureus (n=119). Out of 119 isolates of Staphylococcus aureus 37.2% were Cefoxitin sensitive and 62.7% were resistant. All isolates were sensitive to vancomycin (100%) and linezolide (100%) followed by clindamycin (88.1%) and furazolidone (76.2%) and mupirocin (76.2%). Sensitivity towards erythromycin was low 27.7 %. It was also observed that linezolide and vancomycin is an essential factor. This is particularly important considering the increase of resistance and the emergence of multi-drug resistant organisms.

**Table 3: Antibiotic susceptibility pattern in Staphylococcus aureus (n=119)**

<table>
<thead>
<tr>
<th>Susceptibility Pattern</th>
<th>MRSA (%)</th>
<th>MSSA (%)</th>
<th>Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERY-R, CL-S</td>
<td>10 (8.40)</td>
<td>9 (7.56)</td>
<td>19 (15.96)</td>
</tr>
<tr>
<td>ERY-R, CL-R (Constitutive MLSB phenotype)</td>
<td>12 (10.8)</td>
<td>0</td>
<td>12 (10.8)</td>
</tr>
<tr>
<td>ERY-R, CL-S (D Test positive, iMLSB phenotype)</td>
<td>23 (19.32)</td>
<td>14 (11.76)</td>
<td>37 (31.09)</td>
</tr>
<tr>
<td>ERY-R, CL-S (D Test negative, MS phenotype)</td>
<td>29 (23.7)</td>
<td>22 (18.48)</td>
<td>51 (42.85)</td>
</tr>
<tr>
<td>Total</td>
<td>74 (62.18)</td>
<td>45 (38.6)</td>
<td>119 (100)</td>
</tr>
</tbody>
</table>
CONCLUSION

The rate of prevalence of inducible clindamycin resistance may differ from hospital to hospital. Accurate drug susceptibility data are essential to avoid indiscriminate usage of antibiotics on trial and error basis. All Staphylococcus isolates should be checked for inducible clindamycin resistance. In case of positive D-test, it can cause therapeutic failure and in case of negative D-test it confirms the susceptibility to clindamycin. Thus, enables us to provide guideline for the judicial use of antibiotic therapy for clinician. MRSA are also checked to find out the effectiveness of the drug and proper use of clindamycin in MRSA can reduce the use of vancomycin and non-judicious use of glycopeptides. So, it can be concluded from our study that D-test should be routinely performed in microbiology laboratory for every Staphylococcal isolates otherwise clindamycin resistant isolates may be misinterpreted as clindamycin sensitive, resulting in therapeutic failure.

REFERENCES